Biomay Obtains FDA Approval for Manufacturing of Cas9 Nuclease at Headquarters Site

Share

The company announced its successful approval by the U.S. Food and Drug Administration (FDA) for the manufacturing, testing and release of recombinant Cas9 nuclease from its headquarters site. Cas9 is an essential component of CRISPR-based gene editing therapies, including CASGEVY® (exagamglogene autotemcel) developed and launched by Vertex Pharmaceuticals.  

Biomay Obtains FDA Approval for Manufacturing of Cas9 Nuclease at Headquarters Site. Credits: Biomay AG
Biomay Obtains FDA Approval for Manufacturing of Cas9 Nuclease at Headquarters Site. Credits: Biomay AG

Biomay's recent achievement refers to an inspection by the FDA's Center for Biologics Evaluation and Research (CBER) at Biomay's headquarters manufacturing site in Vienna, Seestadt in December 2024.  No observation was found, and no Form FDA 483 was issued by the authority, allowing Biomay's headquarters site to supply Cas9 for the United States.

Biomay operates two independent cGMP manufacturing sites, a headquarters facility in Vienna Seestadt, and a second site in Vienna downtown. The authority’s approval of Biomay's headquarters site represents the company's second successful FDA inspection following the 2023 approval of Biomay's downtown facility. Biomay's headquarters site is a recently constructed, state-of-the-art biomanufacturing facility.

Biomay AG is a privately owned and fully integrated Contract Development and Manufacturing Organization (CDMO) based in Vienna, Austria. Founded in 1984, the expression of recombinant proteins by utilizing E. coli has been Biomay's business focus from the very beginning. Today, Biomay offers cGMP services for manufacturing of therapeutic proteins, plasmid DNA (pDNA) and messenger RNA (mRNA). The company's scope of CDMO services comprises process and analytical development, cell banking, cGMP manufacturing of drug substance and aseptic filling of drug product.

Contact:
Dr. Angela Neubauer, SVP Client Business; E-Mail: request@biomay.com / Biomay AG, Ada Lovelace-Str. 2, A-1220 Vienna, Austria www.biomay.com

Images

Biomay Obtains FDA Approval for Manufacturing of Cas9 Nuclease at Headquarters Site. Credits: Biomay AG
Biomay Obtains FDA Approval for Manufacturing of Cas9 Nuclease at Headquarters Site. Credits: Biomay AG
Download

Subscribe to releases from news aktuell GmbH

Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from news aktuell GmbH

Deutsche Rück Group maintains profit-oriented growth course21.5.2025 11:00:00 CEST | Press release

Düsseldorf, 21 May 2025 – The Deutsche Rück Group further expanded its business in the 2024 financial year while simultaneously strengthening its financial position. Gross premiums written grew in all business areas, rising significantly by 18.3% to around €2.1 billion. Net premiums earned increased by 17.5% to €1.4 billion. Growth came from both international markets and the German domestic market. Total security resources rose by €375.8 million to more than €3.1 billion.

Bertelsmann Stiftung: New white paper: Public AI as a democratic alternative to the concentration of private power20.5.2025 12:00:00 CEST | Press release

Gütersloh, May 20, 2025 The most powerful AI systems of our time were developed and are controlled by a small number of private companies – including OpenAI, Anthropic, Google DeepMind, Meta, and DeepSeek. These companies don’t just dominate the development of models, they control the basic infrastructure of the AI ecosystem: computing capacities, training data, and cloud services. This concentration of power is not just a technological reality – it is a political challenge. It raises a central question: Who designs the systems that are increasingly influencing our society?

fulfillmenttools: Provider of cloud-based order management fulfillmenttools expands client base with Thalia20.5.2025 11:59:00 CEST | Press release

Cologne, May 20, 2025. – Since 2020, fulfillmenttools has been supporting numerous retailers with its order management solutions, helping them create their own omnichannel experience that seamlessly connects brick-and-mortar and online retail. Thalia, the market-leading omnichannel bookseller in German-speaking countries, is now also opting for fulfillmenttools' solutions: The company is currently building its own logistics and production center as part of its ‘Log2025’ logistics strategy with the so-called omnichannel hub in Marl, Westphalia. This also involved analyzing and optimizing its IT infrastructure, subsequently replacing existing order management solutions with a modern, cloud-based order management system from fulfillmenttools—primarily to increase the efficiency of the omnichannel model.

Grünenthal Group: Maren Thurow starts as new Head Global Communications at Grünenthal20.5.2025 11:53:24 CEST | Press release

Aachen, Germany, 20th May 2025 - Maren Thurow has today assumed the role of Vice President and Head Global Communications at Grünenthal. She succeeds Florian Dieckmann, who has played a key role in evolving the company’s Communications department since 2021. In her new position, Maren will oversee Grünenthal’s communications operations across all markets and lead the team based at the company’s headquarters in Aachen. She will report directly to CEO Gabriel Baertschi.

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye